Petros Giannikopoulos

Petros Giannikopoulos's Title

Petros Giannikopoulos holds the esteemed position of Director at IGI Clinical Laboratory. As the Director, he oversees all clinical operations, ensuring the highest standards of diagnostic accuracy and patient care. His leadership is pivotal in guiding the laboratory's strategic direction, fostering innovation, and maintaining compliance with regulatory standards. Giannikopoulos's role is crucial in integrating advanced genomic technologies into clinical practice, enhancing the laboratory's capabilities in precision medicine.

Petros Giannikopoulos's Education and Expertise

Petros Giannikopoulos boasts an impressive educational background, holding an MD from the prestigious Harvard Medical School. He completed his pathology residency at the University of California, San Francisco, and further specialized in pediatric and molecular pathology at Texas Children’s Hospital and Harvard Medical School. Giannikopoulos is board-certified in anatomic, pediatric, and molecular genetic pathology, showcasing his extensive expertise. His advanced training and certifications underline his proficiency in these intricate fields, making him a sought-after expert in clinical genomics and pathology.

Petros Giannikopoulos's Background

With a diverse and international career, Petros Giannikopoulos has previously served as Laboratory Director for several next-generation sequencing-based clinical genomics laboratories in the United States and Asia. His global experience has equipped him with a broad perspective on clinical genomics, enhancing his ability to implement cutting-edge technologies in varied healthcare environments. Before his current role at the Innovative Genomics Institute, Giannikopoulos was a health technology entrepreneur, where he leveraged his medical and scientific expertise to advance healthcare innovations.

Petros Giannikopoulos's Achievements

Petros Giannikopoulos is a Fellow of the College of American Pathologists, a testament to his significant contributions to the field of pathology. His board certifications in anatomic, pediatric, and molecular genetic pathology highlight his dedication to specialized medicine. Giannikopoulos has been instrumental in leading multiple next-generation sequencing-based clinical genomics labs, driving forward the integration of genomic data in clinical diagnostics. His entrepreneurial ventures in health technology further underscore his commitment to transforming healthcare through innovative solutions.